Category REGULATORY

Corcept

Corcept presented MOMENTUM trial data at the American College of Cardiology Annual Scientific Session

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session Corcept Therapeutics Incorporated a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the…

Read MoreCorcept presented MOMENTUM trial data at the American College of Cardiology Annual Scientific Session
AAD 2026

AAD 2026: Almirall Showcases New Clinical and Real-World Data on Atopic Dermatitis, Psoriasis, Actinic Keratosis, and Acne

AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne Almirall S.A. a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio…

Read MoreAAD 2026: Almirall Showcases New Clinical and Real-World Data on Atopic Dermatitis, Psoriasis, Actinic Keratosis, and Acne
Turn Therapeutics

Turn Therapeutics raises up to $25 million in funding from Avenue Capital Group.

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group Turn Therapeutics, Inc. a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue…

Read MoreTurn Therapeutics raises up to $25 million in funding from Avenue Capital Group.
National Hospital

GenSight Biologics and 15–20 National Hospital begin first GS010/LUMEVOQ® treatments under France’s AAC program.

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME…

Read MoreGenSight Biologics and 15–20 National Hospital begin first GS010/LUMEVOQ® treatments under France’s AAC program.
Coya Therapeutics

Coya Therapeutics reports study linking T-cell dysfunction and inflammation in frontotemporal dementia, supporting COYA 302.

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a…

Read MoreCoya Therapeutics reports study linking T-cell dysfunction and inflammation in frontotemporal dementia, supporting COYA 302.

Veristat Boosts EU Regulatory & Clinical Support for Chinese Pharma and Device Firms

Veristat Expands Regulatory and Clinical Trial Support for Chinese Pharmaceutical and Medical Device Companies Entering Global Markets Veristat, a global contract research organization (CRO) and consulting firm known for its expertise in complex clinical trials, has announced the expansion of…

Read MoreVeristat Boosts EU Regulatory & Clinical Support for Chinese Pharma and Device Firms